U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299019) titled 'A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis' on Dec. 18.
Brief Summary: Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL...